Dharaminder Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dharaminder Singh has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Tomasz Kostrzewski
CN Bio Innovations Ltd, Cambridge, United Kingdom
2 shared publications Adam J. Harding
School of Clinical Dentistry, Claremont Crescent, Sheffield S10 2TN, United Kingdom
1 shared publicationAlysha Bray
Affiliation CN Bio Innovations Limited, Cambridge, United Kingdom
1 shared publicationAntonio Ramos Montoya
Affiliation Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
1 shared publicationChristopher E. Chambers
Affiliation Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
1 shared publication- Clay W. Scott
Affiliation Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America
1 shared publication
Latest Publications
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 182
Abstract 182: Bridging gaps in translational biology: Exploring pharmacokinetic/pharmacodynamic/efficacy relationships and combination treatments in 3D tumor models using a microphysiological system
Accurate profiling of pharmacokinetic (PK) and pharmacodynamic (PD) parameters is critical in the discovery and development of new oncology drugs, schedules and combinations. Predicting these parameters pre-clinically is essential to determine efficacious doses required in clinical treatment. The PK/PD/efficacy relationship has traditionally been characterized in xenograft models, owing to an absence of viable in vitro alternatives. However, murine/human PK parameters can vary for many compounds. To explore PK/PD/efficiency relationships on 3D tumor models and organoids, we have developed a microphysiological system (MPS) able to mimic or reverse translate clinical/in vivo drug exposure (PK) profiles on an in vitro system. The MPS can deliver up to two different drugs to tumor models in monotherapy or combinations, using customizable PK profiles and treatment schedules, by stepwise addition and removal of cell culture medium in a regular 24-well plate format. We first recapitulated the in vivo PK/PD relationship for a PI3K inhibitor (BYL719- t1/2 6 hours, equivalent to 50 mg/kg murine oral dose), used to treat an A549 non-small cell lung carcinoma model. Following BYL719 exposure in the MPS device cellular p-AKT levels (biomarker of PI3K pathway activity) fell by up to 90%, but then recovered to pre-dosed levels over a 24-hour period as drug concentrations in the tumor reduce, as observed in vivo. This effect lacks in standard in vitro bolus experiments. Next, we explored whether the MPS could recapitulate in vivo effects of combining topoisomerase inhibitors with DNA-damage-response inhibitors (DDRi) in the treatment of colorectal tumors. Being almost non-toxic to normal cells, DDRi’s enhance DNA damage induced by topoisomerase inhibitors. 3D colorectal tumor models were treated by the MPS device for six days with monotherapy or combination therapy of the two compounds (SN38 Cmax = 20 nM, DDRi Cmax = 162 nM), recapitulating their in vivo PK profiles. Viability assays showed the benefits of combination therapy (viability 48.5% vs controls) over topoisomerase inhibitor monotherapy (viability 58.3% compared vs controls), with efficacy rates consistent with in vivo observations, rather than static 2D in vitro cultures which were over predictive. Overall, our MPS is able to accurately capture PK/PD/efficacy relationships using in vitro cultures. This approach will enable a greater understanding of drug properties and optimal treatment regimens to ultimately enable better design of clinical studies. Citation Format: Tudor Petreus, Tomasz Kostrzewski, Dharaminder Singh, David Hughes. Bridging gaps in translational biology: Exploring pharmacokinetic/pharmacodynamic/efficacy relationships and combination treatments in 3D tumor models using a microphysiological system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 182.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 182
Open AccessAbstract 182: Bridging gaps in translational biology: Exploring pharmacokinetic/pharmacodynamic/efficacy relationships and combination treatments in 3D tumor models using a microphysiological system
Accurate profiling of pharmacokinetic (PK) and pharmacodynamic (PD) parameters is critical in the discovery and development of new oncology drugs, schedules and combinations. Predicting these parameters pre-clinically is essential to determine efficacious doses required in clinical treatment. The PK/PD/efficacy relationship has traditionally been characterized in xenograft models, owing to an absence of viable in vitro alternatives. However, murine/human PK parameters can vary for many compounds. To explore PK/PD/efficiency relationships on 3D tumor models and organoids, we have developed a microphysiological system (MPS) able to mimic or reverse translate clinical/in vivo drug exposure (PK) profiles on an in vitro system. The MPS can deliver up to two different drugs to tumor models in monotherapy or combinations, using customizable PK profiles and treatment schedules, by stepwise addition and removal of cell culture medium in a regular 24-well plate format. We first recapitulated the in vivo PK/PD relationship for a PI3K inhibitor (BYL719- t1/2 6 hours, equivalent to 50 mg/kg murine oral dose), used to treat an A549 non-small cell lung carcinoma model. Following BYL719 exposure in the MPS device cellular p-AKT levels (biomarker of PI3K pathway activity) fell by up to 90%, but then recovered to pre-dosed levels over a 24-hour period as drug concentrations in the tumor reduce, as observed in vivo. This effect lacks in standard in vitro bolus experiments. Next, we explored whether the MPS could recapitulate in vivo effects of combining topoisomerase inhibitors with DNA-damage-response inhibitors (DDRi) in the treatment of colorectal tumors. Being almost non-toxic to normal cells, DDRi’s enhance DNA damage induced by topoisomerase inhibitors. 3D colorectal tumor models were treated by the MPS device for six days with monotherapy or combination therapy of the two compounds (SN38 Cmax = 20 nM, DDRi Cmax = 162 nM), recapitulating their in vivo PK profiles. Viability assays showed the benefits of combination therapy (viability 48.5% vs controls) over topoisomerase inhibitor monotherapy (viability 58.3% compared vs controls), with efficacy rates consistent with in vivo observations, rather than static 2D in vitro cultures which were over predictive. Overall, our MPS is able to accurately capture PK/PD/efficacy relationships using in vitro cultures. This approach will enable a greater understanding of drug properties and optimal treatment regimens to ultimately enable better design of clinical studies. Citation Format: Tudor Petreus, Tomasz Kostrzewski, Dharaminder Singh, David Hughes. Bridging gaps in translational biology: Exploring pharmacokinetic/pharmacodynamic/efficacy relationships and combination treatments in 3D tumor models using a microphysiological system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 182.
- Open Access
- 26 May 2022
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 20 (5) , e3001624
A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models
Test compounds used on in vitro model systems are conventionally delivered to cell culture wells as fixed concentration bolus doses; however, this poorly replicates the pharmacokinetic (PK) concentration changes seen in vivo and reduces the predictive value of the data. Herein, proof-of-concept experiments were performed using a novel microfluidic device, the Microformulator, which allows in vivo like PK profiles to be applied to cells cultured in microtiter plates and facilitates the investigation of the impact of PK on biological responses. We demonstrate the utility of the device in its ability to reproduce in vivo PK profiles of different oncology compounds over multiweek experiments, both as monotherapy and drug combinations, comparing the effects on tumour cell efficacy in vitro with efficacy seen in in vivo xenograft models. In the first example, an ERK1/2 inhibitor was tested using fixed bolus dosing and Microformulator-replicated PK profiles, in 2 cell lines with different in vivo sensitivities. The Microformulator-replicated PK profiles were able to discriminate between cell line sensitivities, unlike the conventional fixed bolus dosing. In a second study, murine in vivo PK profiles of multiple Poly(ADP-Ribose) Polymerase 1/2 (PARP) and DNA-dependent protein kinase (DNA-PK) inhibitor combinations were replicated in a FaDu cell line resulting in a reduction in cell growth in vitro with similar rank ordering to the in vivo xenograft model. Additional PK/efficacy insight into theoretical changes to drug exposure profiles was gained by using the Microformulator to expose FaDu cells to the DNA-PK inhibitor for different target coverage levels and periods of time. We demonstrate that the Microformulator enables incorporating PK exposures into cellular assays to improve in vitro–in vivo translation understanding for early therapeutic insight.
- 26 May 2022
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 20 (5) , e3001624
Open AccessA microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models
Test compounds used on in vitro model systems are conventionally delivered to cell culture wells as fixed concentration bolus doses; however, this poorly replicates the pharmacokinetic (PK) concentration changes seen in vivo and reduces the predictive value of the data. Herein, proof-of-concept experiments were performed using a novel microfluidic device, the Microformulator, which allows in vivo like PK profiles to be applied to cells cultured in microtiter plates and facilitates the investigation of the impact of PK on biological responses. We demonstrate the utility of the device in its ability to reproduce in vivo PK profiles of different oncology compounds over multiweek experiments, both as monotherapy and drug combinations, comparing the effects on tumour cell efficacy in vitro with efficacy seen in in vivo xenograft models. In the first example, an ERK1/2 inhibitor was tested using fixed bolus dosing and Microformulator-replicated PK profiles, in 2 cell lines with different in vivo sensitivities. The Microformulator-replicated PK profiles were able to discriminate between cell line sensitivities, unlike the conventional fixed bolus dosing. In a second study, murine in vivo PK profiles of multiple Poly(ADP-Ribose) Polymerase 1/2 (PARP) and DNA-dependent protein kinase (DNA-PK) inhibitor combinations were replicated in a FaDu cell line resulting in a reduction in cell growth in vitro with similar rank ordering to the in vivo xenograft model. Additional PK/efficacy insight into theoretical changes to drug exposure profiles was gained by using the Microformulator to expose FaDu cells to the DNA-PK inhibitor for different target coverage levels and periods of time. We demonstrate that the Microformulator enables incorporating PK exposures into cellular assays to improve in vitro–in vivo translation understanding for early therapeutic insight.
- Open Access
- 1 September 2018
- Published by Elsevier in Acta Biomaterialia
- Vol. 78, 48-63
Additive manufactured biodegradable poly(glycerol sebacate methacrylate) nerve guidance conduits
- 1 September 2018
- Published by Elsevier in Acta Biomaterialia
- Vol. 78, 48-63
Open AccessAdditive manufactured biodegradable poly(glycerol sebacate methacrylate) nerve guidance conduits